Stem Cells Industry and Beyond: What is the Aftermath of Brüstle?

European Journal of Risk Regulation, Vol. 1, pp. 93-97, 2012

5 Pages Posted: 14 Mar 2012

See all articles by Enrico Bonadio

Enrico Bonadio

City University London - The City Law School

Date Written: 2012

Abstract

On 18 October 2011 the CJEU released its decision in Brüstle v Greenpeace. This is a widely reported case on the exclusion from patentability of inventions related to human embryonic stem cells (HESCs) on morality grounds.

The article aims to verify whether the Brüstle ruling may expose the EU and some of its Member States to a WTO challenge for failing to comply with Article 27(2) TRIPS as well as whether the decision may have an impact in fields other than HESCs and thus be invoked to oppose the issuance, or challenge the validity, of any patent obtained through immoral or unlawful activities.

Keywords: Intellectual Property, Patent, Biotechnology, Human Embryonic Stem Cells, Morality

Suggested Citation

Bonadio, Enrico, Stem Cells Industry and Beyond: What is the Aftermath of Brüstle? (2012). European Journal of Risk Regulation, Vol. 1, pp. 93-97, 2012 , Available at SSRN: https://ssrn.com/abstract=2021365

Enrico Bonadio (Contact Author)

City University London - The City Law School ( email )

London, EC1V OHB
United Kingdom

HOME PAGE: http://www.city.ac.uk/law/

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
231
Abstract Views
1,020
rank
158,718
PlumX Metrics